2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163984
    Antibacterial agent 240 2899202-97-0 98%
    Antibacterial agent 240 (compound 62-7c) is an antibacterial agent that can target multidrug-resistant (MDR) MRSA strains. Antibacterial agent 240 showed high biosafety and potent anti-infection activity in mouse pneumonia and mouse wound models of MRSA infection.
    Antibacterial agent 240
  • HY-163997
    Antimalarial agent 42 98%
    Antimalarial agent 42 (Compound 2) is an antimalarial agent, that inhibits Plasmodium falciparum in the phase of asexual blood stages (IC50 <0.5μM) and gametocytes (IC50 is 0.14 μM).
    Antimalarial agent 42
  • HY-164109
    Tafuramycin A 494868-78-9 98%
    Tafuramycin A, a Duocarmycin derivative, is a potent anticancer and parasite attenuating agent. Tafuramycin A can be used for triple-negative breast cancer (TNBC) and malaria infection research.
    Tafuramycin A
  • HY-164123
    Antibiofilm agent-9 2001602-07-7 98%
    Antibiofilm agent-9 (Compound 4) is a pyrrolomycin derivative with antibacterial activity. Antibiofilm agent-9 inhibits Bacillus anthracis with MIC of 0.031 μg/mL. Antibiofilm agent-9 exhibits antibiofilm activity with 84% biofilm inhibition (24 h, 8.0 μg/mL). Antibiofilm agent-9 exhibits a good pharmacokinetic characters in mouse model.
    Antibiofilm agent-9
  • HY-164207
    VLPA-GlcNAc 474644-34-3 98%
    VLPA-GlcNAc is a chromogenic glucosaminide substrate. VLPA-GlcNAc can be used to prepare agar media for the identification of Candida spp.
    VLPA-GlcNAc
  • HY-164290
    Rhodady C10 1367579-04-1 98%
    Rhodady C10 (Compound C10) is a dynamin I GTPase inhibitor. Rhodady C10 blocks receptor-mediated endocytosis (IC50: 7 μM). Dynamin is involved in clathrin-independent endocytosis, phagocytosis, and caveolae internalization.
    Rhodady C10
  • HY-164619
    CDK9-IN-34 252725-86-3 98%
    CDK9-IN-34 (Compound 1b) is an inhibitor for CDK9 with an IC50 of 0.25 μM. CDK9-IN-34 exhibits cytotoxicity to cancer cell HCT116, MCF7 and K652 with IC50s of 1.43, 3.01 and 50.27 μM, respectively. CDK9-IN-34 exhibits antiviral activity against coronavirus 229E with an IC50 of 145.92 μM.
    CDK9-IN-34
  • HY-164682
    AMD 3329 octahydrobromide 170861-77-5 98%
    AMD 3329 octahydrobromide is a potent and selective anti-HIV-1 and HIV-2 compound with activity to inhibit viral replication. AMD 3329 blocks viral invasion by binding to the chemokine receptor CXCR4. AMD 3329 exhibits EC50 values as low as 0.8 and 1.6 nM when inhibiting HIV-1 and HIV-2 replication, showing better antiviral efficacy than AMD3100. AMD 3329 significantly inhibits the binding of specific CXCR4 monoclonal antibodies and the Ca(2+) flux induced by SDF-1alpha. AMD 3329 is also able to effectively interfere with virus-induced syncytium formation, with an EC50 value of 12 nM.
    AMD 3329 octahydrobromide
  • HY-164752
    6‑Hydroxy‑FAD 52301-43-6
    6-hydroxy-FAD is the dominant cofactor of H. insolens Cellobiose dehydrogenases. the activity of Cellobiose dehydrogenases containing 6-hydroxy-FAD is lower than that of the enzyme reconstituted with normal FAD.
    6‑Hydroxy‑FAD
  • HY-165272
    Antibiotic SF-2132 87003-23-4 98%
    Antibiotic SF-2132 is a peptide antibiotic identified in Nocardiopsis sp., which exhibits inhibitory activity against β-lactam antibiotic-resistant strains, such as Pseudomonas and Escherichia.
    Antibiotic SF-2132
  • HY-165368
    Atromentin 519-67-5 98%
    Atromentin, a phthalide derivative that can be isolated from the wood fungus Hypoxylon fendleri BCC32408, is a selective enoyl-ACP reductase FabK inhibitor with an IC50 of 0.24 μM. Atromentin exhibits selectivity over FabI. Atromentin can be used for antimicrobial research.
    Atromentin
  • HY-165440
    Cyclobenzaprine 303-53-7 98%
    Cyclobenzaprine (MK130) is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Cyclobenzaprine also possesses antiparasitic activity. Cyclobenzaprine holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases.
    Cyclobenzaprine
  • HY-165459
    KJM429 401907-57-1
    KJM429 (MK-056) is a high-affinity ligand for the rat vanilloid receptor rTRPV1 (Ki=30-63 nM) with a unique dual regulatory function. KJM429 acts as a competitive antagonist to inhibit TRPV1 receptor activation induced by Capsaicin (HY-10448), resiniferatoxin, thermal stimulation and weak acid (pH 6.0), and switches to a TRPV1 agonist under strong acid conditions (pH<5.5). KJM429 effectively blocks calcium influx induced by Capsaicin and partial thermal stimulation, and triggers calcium uptake under low pH conditions, with minimal effects on non-TRPV1-mediated calcium signaling. KJM429 can be used for research on the mechanisms of pain-related diseases such as postherpetic neuralgia, diabetic neuropathy, cluster headache, osteoarthritis and pruritus.
    KJM429
  • HY-165485
    OSL-95II 946603-07-2
    OSL-95II is an antiviral agent. OSL-95II is a potent BVDV and WNV inhibitor. OSL-95II is a better inhibitor of HBV than SP169. OSL-95II inhibits dengue virus production.
    OSL-95II
  • HY-165513
    Niruriside 173268-90-1
    Niruriside is a HIV REV/RRE complex inhibitor. Niruriside specifically inhibits the binding interaction between HIV REV protein and RRE RNA, with an IC50 of 3.3 μM, and shows no significant activity against the unrelated R17 capsid protein/operator RNA binding system. At the tested concentrations, Niruriside fails to protect CEM-SS cells from acute HIV-1 infection. Niruriside can be used in the research of human immunodeficiency virus (HIV) infection.
    Niruriside
  • HY-165540
    BDM31343 1001468-07-0 98%
    BDM31343 is an Ethionamide (HY-B0276) synergist. BDM31343 inhibits the transcriptional repressor EthR in Mycobacterium tuberculosis, thereby relieving the inhibition of the EthA activator by Ethionamide, and enhancing the efficacy of Ethionamide. BDM31343 effectively inhibits the binding of EthR to DNA, with its IC₅₀ being 3.3 μM. BDM31343 can be used in the research of anti-Mycobacterium tuberculosis.
    BDM31343
  • HY-165555
    MMV665917 904576-65-4
    MMV665917 is an orally active piperazine derivative with anti-Cryptosporidium parvum activity with an EC90 of 15 μM. MMV665917 significantly reduces the parasite load in a porcine model infected with C. hominis, decreases ovarian excretion, alleviates diarrhea symptoms and reduces intestinal mucosal damage. MMV665917 can be used for research on Cryptosporidium parvum disease.
    MMV665917
  • HY-16560R
    Camptothecin (Standard) 7689-03-4 98%
    Camptothecin (Standard) (Campathecin (Standard)) is the analytical standard of Camptothecin (HY-16560). This product is intended for research and analytical applications. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.
    Camptothecin (Standard)
  • HY-16561G
    Resveratrol (GMP) 501-36-0 98%
    Resveratrol (GMP) is Resveratrol (HY-16561) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
    Resveratrol (GMP)
  • HY-16589R
    Oligomycin A (Standard) 579-13-5
    Oligomycin A (Standard) is the analytical standard of Oligomycin A. This product is intended for research and analytical applications. Oligomycin A (MCH 32), created by Streptomyces, acts as a mitochondrial F0F1-ATPase inhibitor, with a Ki of 1 μM; Oligomycin A shows anti-fungal activity.
    Oligomycin A (Standard)
Cat. No. Product Name / Synonyms Application Reactivity